Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Moodys
McKesson
Express Scripts
Johnson and Johnson
Medtronic
Mallinckrodt

Last Updated: November 28, 2022

CLINICAL TRIALS PROFILE FOR EC-NAPROSYN


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


All Clinical Trials for Ec-naprosyn

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00153660 ↗ Celecoxib Versus Naproxen for Prevention of Recurrent Ulcer Bleeding in Arthritis Patients Completed Chinese University of Hong Kong Phase 3 2005-06-01 The aim of this study is to compare celecoxib plus a PPI (esomeprazole) versus naproxen plus a PPI (esomeprazole) in preventing recurrent ulcer bleeding in arthritis patients with a history of ulcer bleeding who require concomitant ASA. We hypothesized that among patients with a history of ulcer bleeding who require concomitant ASA, celecoxib plus esomprazole would be superior to naproxen plus esomeprazole for the prevention of recurrent ulcer bleeding.
NCT00303017 ↗ Safety, Efficacy and Acceptability of Flavocoxid (Limbrel)A Pilot Study Completed Primus Pharmaceuticals N/A 2006-03-01 safety, efficacy and acceptability of Flavocoxid
NCT00383487 ↗ A Phase II Trial of Calcitriol and Naproxen in Patients With Recurrent Prostate Cancer Terminated Novacea Phase 2 2005-03-01 To determine whether, in this patient population, treatment with calcitriol and Naproxen is more effective in delaying the growth of prostate cancer than treatment with calcitriol alone as seen in historical controls.
NCT00383487 ↗ A Phase II Trial of Calcitriol and Naproxen in Patients With Recurrent Prostate Cancer Terminated Stanford University Phase 2 2005-03-01 To determine whether, in this patient population, treatment with calcitriol and Naproxen is more effective in delaying the growth of prostate cancer than treatment with calcitriol alone as seen in historical controls.
NCT00435292 ↗ Study of Flavocoxid (Limbrel) vs Naproxen in Subjects With Mod-Severe Osteoarthritis of the Knee Completed Primus Pharmaceuticals N/A 2006-04-01 Randomized, double-blind, placebo controlled parallel group, multi center study in subjects with moderate-severe osteoarthritis.
NCT00527787 ↗ Evaluating PN 400 (VIMOVO) in Reducing Gastric Ulcers Compared to Non-steroidal Antiinflammatory Drug (NSAID) Naproxen Completed POZEN Phase 3 2007-09-01 This study uses a randomized, double-blind, controlled design to demonstrate that PN400 (esomeprazole and naproxen) is more effective in reducing the occurrence of gastroduodenal ulcers, dyspepsia, and heartburn in subjects at risk for developing NSAID-associated gastric ulcers compared to naproxen alone.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Ec-naprosyn

Condition Name

Condition Name for Ec-naprosyn
Intervention Trials
Osteoarthritis 7
Healthy 5
Gastric Ulcer 4
Chronic Low Back Pain 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Ec-naprosyn
Intervention Trials
Osteoarthritis 8
Stomach Ulcer 5
Back Pain 4
Osteoarthritis, Knee 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Ec-naprosyn

Trials by Country

Trials by Country for Ec-naprosyn
Location Trials
United States 56
Canada 5
Sweden 4
United Kingdom 2
Thailand 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Ec-naprosyn
Location Trials
Illinois 6
New York 5
Pennsylvania 4
Utah 3
Maryland 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Ec-naprosyn

Clinical Trial Phase

Clinical Trial Phase for Ec-naprosyn
Clinical Trial Phase Trials
Phase 4 7
Phase 3 5
Phase 2/Phase 3 2
[disabled in preview] 18
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Ec-naprosyn
Clinical Trial Phase Trials
Completed 29
Unknown status 6
Withdrawn 4
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Ec-naprosyn

Sponsor Name

Sponsor Name for Ec-naprosyn
Sponsor Trials
National Institutes of Health (NIH) 6
Northwestern University 5
AstraZeneca 4
[disabled in preview] 10
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Ec-naprosyn
Sponsor Trials
Other 29
Industry 26
NIH 13
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Harvard Business School
Boehringer Ingelheim
McKesson
Colorcon
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.